FDA approves Novo Nordisk’s oral GLP-1 pill for weight loss
The approval expands the Wegovy portfolio beyond injections, providing a new administration option for patients.
GLP-1s
Novo Nordisk files FDA application for once-weekly obesity treatment
“The FDA submission of CagriSema marks an important milestone and signals a new era in weight management,” said Novo Nordisk CEO.
Novo Nordisk seeks FDA approval for 7.2 mg Wegovy dose
If accepted, the agency is expected to complete its review within one to two months.
retailmediaIQ hosts Re-imagining Women’s Wellness webcast
Industry leaders from NielsenIQ, WSL Strategic Retail, and Think Blue will discuss the forces driving women’s health innovation.
Novo Nordisk cuts prices on Wegovy and Ozempic
The company reduced its prices following pressure from the Trump administration, which urged the company and competitor Eli Lilly to lower the cost of widely used weight-loss and diabetes drugs.
retailmediaIQ + NIQ + Think Blue: Re-imagining Women’s Wellness webinar
Save the Date: Tuesday, November 25, 2:00 p.m. ET.
Trump strikes historic deal to cut drug prices
Prices for Wegovy, Ozempic, and Zepbound drop from over $1,000 to $350 with the new deal. Medicare coverage begins for GLP-1 obesity drugs for the first time.
GNC review links supplements to GLP-1 wellness
The review outlines practical supplement strategies to help clinicians support muscle health, heart function, and digestion in patients using GLP-1 therapies.
Sam’s Club expands same-day delivery to refrigerated medications
Sam’s Club is extending its pharmacy services with free same-day delivery of refrigerated medications for Plus Members, including GLP-1s, insulin and other specialty prescriptions.
Costco to offer Ozempic and Wegovy at $499 for members
That amount is approximately half the list price for Ozempic and about one-third lower than Wegovy.
Protein takes center stage in consumer health priorities
Consumers seek protein throughout the day. Breakfast is the main entry point, but there are innovations in snacks, indulgent foods, and dinners.
Lilly’s oral GLP-1 drug nears global filing
Lilly’s oral GLP-1 pill helped patients lose 22 pounds and lower A1C in a Phase 3 trial, with global filings planned this year.
Canada authorizes Ozempic for kidney and heart protection in diabetes
Health Canada approved Ozempic to slow kidney disease and reduce heart deaths in type 2 diabetes, a first-of-its-kind approval that could help millions.
Weight loss drugs may help prevent stroke and reduce complications, studies show
GLP-1 inhibitors linked to reduced mortality and fewer cognitive problems after stroke and brain hemorrhage, according to three studies.
Employers rethink GLP-1 coverage as costs soar
Prescription drug spending overall increased by 8% last year, with Mercer projecting a 5.8% rise in total health benefit costs for 2025.
Major insurance change hits users of Zepbound for weight loss
Millions of patients using GLP-1 drugs for weight loss could see costs skyrocket.